Last reviewed · How we verify
NCT03620318
Individual Patient Compassionate Use of Crenolanib
trial testing Crenolanib besylate in FLT3-ITD Mutation. Available.
Quick facts
| Lead sponsor | Arog Pharmaceuticals, Inc. |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Crenolanib besylate — full drug profile →
Conditions studied
- FLT3-ITD Mutation — all drugs for FLT3-ITD Mutation →
- FLT3/TKD Mutation — all drugs for FLT3/TKD Mutation →
- PDGFR-Alpha D842V — all drugs for PDGFR-Alpha D842V →
- PDGFRA Gene Amplification — all drugs for PDGFRA Gene Amplification →
Sponsor
Arog Pharmaceuticals, Inc. — full company profile →
Who can join
Eligibility, any sex, with FLT3-ITD Mutation or FLT3/TKD Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Compassionate use of crenolanib for patients with serious life-threatening illness that have exhausted all available therapies used to treat the disease, with no other viable therapy options, who is not eligible for clinical trials. This program is designed to evaluate the requests on a patient by patient basis. Patients must have documented evidence of a point mutation in position 842 in platelet derived growth factor receptor alpha (PDGFRA-D842V) or amplification of PDGFRA or internal tandem duplication within the FMS-like tyrosine kinase 3 (FLT3-ITD) or point mutations within the tyrosine kinase domain (TKD) of FLT3 (FLT3-TKD)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03620318
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for FLT3-ITD Mutation
Currently open trials in the same condition.
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
Other Arog Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT03250338 — Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML · Phase 3 · completed
- NCT03258931 — Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mu · Phase 3 · completed
- NCT03193918 — Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03620318 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Arog Pharmaceuticals, Inc.
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03620318.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing